TAP Prevacid pediatric indication
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
TAP's proton pump inhibitor Prevacid (lansoprazole) clears FDA July 31 for the short-term treatment of symptomatic gastroesophageal reflux disease and erosive esophagitis in children one to 11 years old. The Abbott/Takeda joint venture is highlighting Prevacid as the only PPI available in an oral suspension formulation, a potential advantage for children who have difficulty swallowing capsule